In one study, the positive-acting enzyme ACSL4, whose expression is independent of sorafenib treatment in HCC cell lines, can serve as a promising predictive and validated biomarker that contributes to the precise treatment of HCC that is superior to that involving Rb 123. Here, ACSL4 is linked to hepatocellular carcinoma.